iBio, Inc.’s Post

🌟 iBio, Inc. is proud to attend the Antibody Engineering & Therapeutics Conference in our hometown of San Diego this week! 🌟 Our leaders, Kristi Sarno, SVP of Business Development, and Cory Schwartz, Director of Drug Discovery, are on the ground representing iBio’s cutting-edge advancements in AI-driven antibody discovery and development. This event is pivotal for showcasing how iBio's Machine Learning Antibody Discovery Engine and technologies like Epitope Steering, ShieldTx™, and EngageTx™ are accelerating the creation of first-in-class and best-in-class therapeutics. By addressing hard-to-drug targets and reducing preclinical timelines, we're shaping the future of cardio-metabolic therapeutics and immuno-oncology drugs. As San Diego continues to thrive as a biotech hub, our presence reflects iBio's commitment to innovation and collaboration within this vibrant #biotech ecosystem. Conferences like these are where strategic partnerships form, groundbreaking ideas emerge, and the future of antibody engineering takes shape. 💡 Let’s connect! If you’re at the conference, we’d love to discuss how #iBio can support your pipeline goals or explore partnership opportunities. #AntibodyEngineering #MachineLearning #ImmunoOncology #SanDiegoBiotech #Collaboration #iBio

🔬 Artbio Raises $90M Series A for Radiopharmaceutical Innovation TL;DR: • $90M Series A led by Third Rock Ventures • Key executive hires from Novartis • 3 programs in development pipeline • Growing sector with major pharma interest Exciting developments in the radiopharmaceutical space! Artbio has secured $90M in Series A funding, building on their $23M seed round. This substantial investment signals growing confidence in precision radiation-based cancer treatments. The company is strengthening its leadership with strategic hires: • Philippe Dasse → Chief Technology Officer • Daniel Rossetto → SVP of Supply Chain & External Manufacturing Both executives bring valuable experience from Novartis/Advanced Accelerator Applications. Their lead candidate, AB001, targets prostate cancer using Pb212 isotope technology - offering precise tumor targeting while preserving healthy tissue. The sector is heating up: • Novartis reporting positive GI cancer results • Bayer expanding radiopharmaceutical presence • Eli Lilly entering with $1.4B Point Biopharma acquisition • RayzeBio's recent $311M IPO 💭 What are your thoughts on the future of radiopharmaceuticals in cancer treatment? Share your insights below. #Biotech #CancerResearch #Radiopharmaceuticals #BiotechInvestment #Innovation #intelligencesimplified #pharma #biotech #biodatastudio

ICG Life Sciences led Grey Wolf Therapeutics’s oversubscribed $50 million Series B financing expansion, with further investments from existing investors, Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises and British Patient Capital. Grey Wolf is a clinical-stage biotechnology company harnessing first-of-its-kind antigen modulation therapies to target the source of immune dysfunction in oncology and autoimmunity and our Life Sciences team are proud to be supporting the company through its next phase of growth, bringing these potentially transformational therapies closer to patients. 📰 Read the press release: https://lnkd.in/ezJRw7k8 👩🔬Explore ICG Life Sciences: https://lnkd.in/eGpcKCPd At ICG we: 💡 Provide flexible, sustainable solutions 🎯 Drive performance 💫 Operate with purpose #LifeSciences #Healthcare #PrivateCapital #PrivateMarkets #Alternatives Capital at risk. Past performance is not a reliable indicator of future results.

🚨 atbtherapeutics Secures the Largest Series A in Wallonia: €54M!   A major milestone for Belgian biotech 🇧🇪: ATB Therapeutics, a pioneer in First-in-Class weaponized antibodies, has raised a record-breaking €54M Series A, co-led by EQT Life Sciences and MRL Ventures Fund LLC (@Merck & Co.), with the support of key investors, including Wallonie Entreprendre, V-Bio Ventures, and VIVES Partners.   ➡️ This funding will advance ATB’s revolutionary ATBioFarm platform, enabling the development of next-generation biologics that integrate targeting and cytotoxic functions in a single construct—transforming oncology and immunology treatments. The company also welcomes Mark Throsby as Executive Chair. With his extensive experience in antibody therapeutics, he will help ATB deliver on its mission to bring first-in-class therapies to patients.   This landmark achievement not only cements ATB’s position as a biotech trailblazer but also highlights Wallonia as a leader in global innovation. 🌍   Read the complet story in La Libre (links in the comments) 👇   Contact our team for your financial needs in Life Sciences (links in the comments) 👇   #lifesciences #funding

Alumis, an 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 on the cusp of 𝐏𝐡𝐚𝐬𝐞 𝟑, has secured $𝟐𝟓𝟎𝐌 𝐢𝐧 𝐚 𝐬𝐡𝐫𝐮𝐧𝐤𝐞𝐧 𝐈𝐏𝐎. The Bay Area startup sold 𝟏𝟑.𝟏𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 𝐚𝐭 $𝟏𝟔 𝐞𝐚𝐜𝐡 to fund the late-stage testing of its lead 𝐓𝐘𝐊𝟐 𝐝𝐫𝐮𝐠, studies of a second asset in neuroinflammatory conditions, and preclinical projects. While the IPO was smaller than initially projected, an additional 𝟐.𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 were sold in a concurrent private placement. With $𝟑𝟒𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐥𝐥𝐨𝐜𝐚𝐭𝐞𝐝 toward clinical development, Alumis aims to create a next-gen immunology treatment, facing competition from Bristol Myers Squibb’s Sotyktu and Takeda’s TAK-279. Alumis has spent heavily on R&D, with $𝟏𝟑𝟕 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐥𝐚𝐬𝐭 𝐲𝐞𝐚𝐫 𝐚𝐧𝐝 $𝟏𝟎𝟏 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐. The company, led by Martin Babler, hopes to buck the trend of biotechs trading below their IPO price. https://lnkd.in/eK_H6kda #Biotech #Immunology #IPO #Pharma #HealthcareInnovation

🔊𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 𝗡𝗲𝘄𝘀   We are thrilled to share that one of our portfolio companies, PhoreMost Ltd., has successfully raised $𝟧𝟢𝖬 𝗂𝗇 𝖺 𝖲𝖾𝗋𝗂𝖾𝗌 𝖡 𝖿𝗂𝗇𝖺𝗇𝖼𝗂𝗇𝗀 𝗋𝗈𝗎𝗇𝖽.   Phoremost, a University of Cambridge spinout, is developing a next-generation phenotypic screening platform called SITESEEKER®, which can identify the best new targets for future therapies and, crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancers and other diseases of unmet need.   The investment will enable them to advance its oncology and inflammation programs towards preclinical development. The funding will also further deploy their platform for molecular glue design and expand pharma collaborations. Read the full press release here: https://lnkd.in/eTxfpQDP    #o2hVentures #portfolio #eis #seis #news

Biogen's Billion Dollar Bet: Can This Antibody Be a Pipeline in a Product? 5 Key Points for Investors on Biogen's Acquisition of HI-Bio: 1) Diversification Play: Biogen is heavily invested in neuroscience, and CEO Chris Viehbacher sees this as a risk. Buying HI-Bio allows Biogen to expand into immunology, a growing market with promising potential. 2) Promising Late-Stage Asset: The key driver here is felzartamab, an anti-CD38 monoclonal antibody entering phase 3 trials for multiple rare immune-mediated diseases. Early data shows positive impact on biomarkers and clinical endpoints in kidney diseases with significant unmet needs. 3) Pipeline-in-a-Product Potential: Felzartamab's ability to target various diseases (PMN, AMR, IgAN, potentially lupus) creates a broad development program. If successful, Biogen gains a significant foothold in immunology with a single platform. 4) Leveraging Expertise: Biogen plans to utilize its existing capabilities in rare disease development and commercialization for felzartamab. They also aim to retain HI-Bio's talent and establish an immunology team in the San Francisco Bay Area. 5) Bonus Asset: Beyond felzartamab, Biogen acquires a phase 1 anti-C5aR1 antibody for complement-mediated diseases, adding further value to the deal. My take: This acquisition looks like a strategic move for Biogen to lessen its dependence on neuroscience and enter the high-growth immunology space. Felzartamab's potential across multiple rare diseases is particularly exciting, but success hinges on phase 3 clinical trials. Investors should carefully monitor these trials and the overall integration of HI-Bio's assets into Biogen's pipeline. As an investor, what do you think about this diversification move? Leave your comments below. Share this news with your investor buddies. They’ll thank you later. 🗣️ #biotech #investment #investor #vc #drug #healthcare #market #business #immunology #acquisition #pharmaceutical #company #innovation _________________________________________________________________________________ Biotech investor or innovator? We assist investors unlock potential by assisting with due diligence and companies refine strategies for success and get bigger exposure to investors. Send me a DM and let´s connect Follow me, hit the 🔔 Adrian Rubstein

Iambic Therapeutics announced the closing of an oversubscribed $50 million extension to its Series B financing. The Series B extension was funded by new investors Mubadala Capital, Exor Ventures and the Qatar Investment Authority (QIA), and existing investors Abingworth, Illumina Ventures, Nexus Ventures, Coatue, and Tao Capital. The extension adds to an oversubscribed $100 million Series B that closed in October and was co-led by Ascenta Capital and Abingworth, joined by NVIDIA and others.    Iambic Therapeutics' physics-informed AI-driven discovery platform has enabled a pipeline of novel small molecule therapeutics, including IAM1363, a highly selective, brain-penetrant inhibitor of wild-type and oncogenic mutant HER2 proteins currently in Phase 1 studies, and IAM-C1, a potential first-in-class selective dual CDK2/4 inhibitor. Proceeds from a combined >$150M Series B financing will be used to broaden and accelerate Iambic's clinical and pre-clinical oncology programs.    Ron Mazumder Charles Lin Bill Rastetter     Read the full press release: https://lnkd.in/eQk6jD96    This news follows another exciting announcement earlier that Thomas Miller, CEO of Iambic Therapeutics, has received the EY Entrepreneur Of The Year® 2024 Pacific Southwest Award. See EY’s full press release here: https://lnkd.in/eUShge_T Way to go, Tom!    #partnernews #SeriesB #biotech #lifescience #MachineLearning #AI #DrugDiscovery #healthcare

🌟 Exciting News in the Biotech World last week of october ! 🌟 🔬 Pfizer has expanded its protein degradation toolbox with a $49M deal with TRIANA Biomedicines, potentially reaching up to $1.5Bn in milestones. This collaboration aims to discover molecular glue degraders for cancer and other diseases through Triana's innovative discovery platform. 💊 Novartis has secured worldwide rights to an undisclosed antitumor small molecule from Chengdu Baiyu Pharmaceutical for $70M upfront, with potential milestones up to $1.1Bn. Baiyu's focus on targeted radiopharmaceuticals and immunotherapies is set to make waves in oncology. 🌐 OCEAN BIOMEDICAL has gained rights to CHI3L1 (YKL40) inhibitor OAT-3912 from Molecure, showing promising therapeutic effects in preclinical cancer models. 🧬 Takeda has decided not to exercise its option to license WVE-003 from Wave Life Sciences, ending their collaboration. However, Wave plans to advance the Huntington program, with interim data showing significant reductions in mutant HTT. #Biotech #Pharma #Innovation #Healthcare #Research #venture #bpifrance

2024 has been an exciting year for several #SBIR-funded #Biotech startups, including RadioMedix, which received several awards from our program for its AlphaMedix innovation. Not only did it become the first Targeted Alpha Therapy (TAT) to receive FDA Breakthrough Therapy Designation, but the company completed a $110 million licensing agreement this fall with Sanofi and Orano Med! Learn how this technology aims to provide a new treatment option for adult patients with unresectable or metastatic, progressive somatostatin-receptor expressing neuroendocrine tumors (NETs). https://lnkd.in/eYB6psqS